in the absence of a submission from the holder of the marketing authorisation
nilotinib (Tasigna®) is not recommended for use within NHS Scotland.
Indication under review:
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
|Drug Name:||nilotinib (Tasigna)|
|SMC Drug ID:||1325/18|
|Manufacturer:||Novartis Pharmaceuticals UK Ltd|
|Indication:||Paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, and Paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib|
|Submission Type:||Non submission|
|Date Advice Published:||12 March 2018|
To read more Press Release articles, click here.